Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Timolol · Betimol, Istalol

Small molecule · Antagonist of beta-1 adrenergic receptor (ADRB1) and beta-2 adrenergic receptor (ADRB2) · developed by Bausch And Lomb

Approved FDA, Aug 1978

BHC Developer

2 Registered trials

What is Timolol?

Timolol is a non-selective beta-adrenergic receptor antagonist applied topically to the eye.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: Betimol, Istalol, Timolol Gfs, Timolol Maleate, L-714465
Drug type: Small molecule
Targets: beta-1 adrenergic receptor (ADRB1), beta-2 adrenergic receptor (ADRB2)
Mechanism: Antagonist of beta-1 adrenergic receptor (ADRB1) and beta-2 adrenergic receptor (ADRB2)
Pathways: aqueous humor formation
Therapy area: Ophthalmology
Developer: Bausch And Lomb Inc (BHC)
Also in trials of: SMMT
FDA status: Approved as Betimol, Istalol, Timolol Gfs (August 17, 1978), NDA018086 · FDA label
UNII: 2BG20ZUO2E

✅ FDA-approved uses

Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma (Betimol)
Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma (Timolol Maleate)
Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma (Istalol)
Elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma (Timolol Gfs)

From the indications section of the FDA label (version of Jun 27, 2025). Read the full label for the exact wording, limitations and safety information.

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT07168902	Phase 2	Glaucoma	Completed	BHC
NCT04910100	Phase 2	Open-Angle Glaucoma	Completed	SMMT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

GlaucomaOcular HypertensionOpen-Angle Glaucoma

Other drugs acting on ADRB1 / ADRB2

Albuterol FDA approved Epinephrine FDA approved Bedoradrine Phase 2

More from Bausch And Lomb

Adapalene / Benzoyl Peroxide / Clindamycin FDA approved Brodalumab FDA approved Bupropion FDA approved Halobetasol Propionate And Tazarotene FDA approved IDP-118 FDA approved IDP-126 FDA approved Lifitegrast FDA approved Perfluorohexyloctane FDA approved Plecanatide FDA approved Rifaximin FDA approved BL1107 Phase 2 BL1332 Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the BHC page.

Follow BHC, the company behind Timolol

See BHC's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BHC catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z